Autoantibodies in Polymyositis / Dermatomyositis · suffering from polymyositis, scleroderma or...
1
DIARECT AG · Bötzinger Str. 29 B · 79111 Freiburg · Germany Tel. +49 761 47979-0 · Fax +49 761 47979-29 · [email protected] · www.diarect.com Autoantibodies in Polymyositis / Dermatomyositis 181108_Rev01 Inflammatory myopathies are characterized by the pres- ence of inflammatory infiltrates within skeletal muscle. These idiopathic myopathies encompass a variety of syn- dromes. The common subtypes include adult polymyositis (PM) and dermatomyositis (DM), along with inclusion body myositis, childhood myositis, malignancy-associated myosi- tis, and myositis in overlap with another autoimmune con- nective tissue disease. To date, autoantibodies targeting eight of the 20 aminoacyl- tRNA synthetases have been identified, being found in up to 30% of sera from patients with myositis. They are highly specific for this disorder and strongly associated with complicating lung disease. Anti-SRP antibodies are mainly associated with a syndrome of a necrotizing myopathy with cardiac involvement, severe prognosis and poor response to therapy. Anti-Mi-2 autoantibodies are considered specific serological markers of DM. Detected in about 20% of myositis sera they are proven markers for acute onset, good prognosis and good response to therapy. Autoantibodies against PM/Scl (mainly PM/Scl 100) occur in patients suffering from polymyositis, scleroderma or polymyositis / scleroderma overlap complex. The presence of PM/Scl 100 antibodies is a comparatively “good” prognostic sign in polymyositis / scleroderma overlap syndrome, unlike the poor prognosis seen when other myositis- and systemic sclerosis-specific antibodies are present. More recent publications describe a number of novel auto- antibodies especially in dermatomyositis patients. Autoan- tibodies to anti-p155/140 (TIF1 gamma) are found in up to 20% of patients with dermatomyositis. A strong link with cancer associated myositis was shown in anti-TIF1 gamma positive patient cohorts. Autoantibodies to a 140-kDa cytoplasmic protein (MDA5) have been mainly reported in Asian patients suffering from dermatomyositis. Also, the occurrence of this novel autoantibody was shown to be associated with interstitial lung disease. DIARECT’s recombinant autoantigens are produced in the baculovirus / insect cell expression system. They all have a proven track record for quality and sensitivity. Ordering Information 12900 12901 Histidyl-tRNA Synthetase (Jo-1) 0.1 mg 1.0 mg 15600 15601 15700 15701 Threonyl-tRNA Synthetase (PL-7) Alanyl-tRNA Synthetase (PL-12) 0.1 mg 1.0 mg 0.1 mg 1.0 mg 11100 11101 30100 30101 18400 18401 16000 16001 17000 17001 18100 18101 11000 11001 30000 30001 Glycyl-tRNA Synthetase (EJ) Asparaginyl-tRNA Synthetase (KS) SRP54 PM/Scl 100 PM/Scl 75 Mi-2 TIF1 gamma MDA5 0.1 mg 1.0 mg 0.1 mg 1.0 mg 0.1 mg 1.0 mg 0.1 mg 1.0 mg 0.1 mg 1.0 mg 0.1 mg 1.0 mg 0.1 mg 1.0 mg 0.1 mg 1.0 mg Figure: Immunodot analyses of negative (BD) and positive samples (PS1 - PS 8) for myositis. The presense of myositis autoantibodies was deter- mined by spotting decreasing amounts of selected recombinant myosi- tis antigens produced in the baculovirus / insect cell expression system. Proteins and controls (HSA, anti-IgGMA and hum IgG) were printed on nitrocellulose membrane as indicated. References: Betteridge et al. (2011) Arthritis Research & Therapy. 13:209-215 Hoshino et al. (2010) Rheumatology. 49:1726-1733 In some countries the use of certain antigens in diagnostic tests may be protected by patents. DIARECT is not responsible for the determination of these issues and suggests clarification prior to use. HSA anti-IgGMA hum IgG HSA anti-IgGMA hum IgG Jo-1 PL-7 PL-12 EJ KS SRP54 Mi-2 TIF1 gamma MDA5 PM/Scl 100 PM/Scl 75 HSA anti-IgGMA hum IgG HSA anti-IgGMA hum IgG Jo-1 PL-7 PL-12 EJ KS SRP54 Mi-2 TIF1 gamma MDA5 PM/Scl 100 PM/Scl 75 HSA anti-IgGMA hum IgG HSA anti-IgGMA hum IgG Jo-1 PL-7 PL-12 EJ KS SRP54 Mi-2 TIF1 gamma MDA5 PM/Scl 100 PM/Scl 75 PS 4 PS 1 PS 2 PS 5 PS 7 PS 8 HSA anti-IgGMA hum IgG PS 3 HSA anti-IgGMA hum IgG PS 6 HSA anti-IgGMA hum IgG BD
Transcript of Autoantibodies in Polymyositis / Dermatomyositis · suffering from polymyositis, scleroderma or...
-
DIARECT AG · Bötzinger Str. 29 B · 79111 Freiburg · GermanyTel. +49 761 47979-0 · Fax +49 761 47979-29 · [email protected] · www.diarect.com
Autoantibodies in Polymyositis / Dermatomyositis
181108_Rev01
Inflammatory myopathies are characterized by the pres-ence of inflammatory infiltrates within skeletal muscle. These idiopathic myopathies encompass a variety of syn-dromes. The common subtypes include adult polymyositis (PM) and dermatomyositis (DM), along with inclusion body myositis, childhood myositis, malignancy-associated myosi-tis, and myositis in overlap with another autoimmune con-nective tissue disease.
To date, autoantibodies targeting eight of the 20 aminoacyl-tRNA synthetases have been identified, being found in up to 30% of sera from patients with myositis. They are highly specific for this disorder and strongly associated with complicating lung disease. Anti-SRP antibodies are mainly associated with a syndrome of a necrotizing myopathy with cardiac involvement, severe prognosis and poor response to therapy. Anti-Mi-2 autoantibodies are considered specific serological markers of DM. Detected in about 20% of myositis sera they are proven markers for acute onset, good prognosis and good response to therapy. Autoantibodies against PM/Scl (mainly PM/Scl 100) occur in patients suffering from polymyositis, scleroderma or polymyositis / scleroderma overlap complex. The presence of PM/Scl 100 antibodies is a comparatively “good” prognostic sign in polymyositis / scleroderma overlap syndrome, unlike the poor prognosis seen when other myositis- and systemic sclerosis-specific antibodies are present.
More recent publications describe a number of novel auto-antibodies especially in dermatomyositis patients. Autoan-tibodies to anti-p155/140 (TIF1 gamma) are found in up to 20% of patients with dermatomyositis. A strong link with cancer associated myositis was shown in anti-TIF1 gamma positive patient cohorts. Autoantibodies to a 140-kDa cytoplasmic protein (MDA5) have been mainly reported in Asian patients suffering from dermatomyositis. Also, the occurrence of this novel autoantibody was shown to be associated with interstitial lung disease.
DIARECT’s recombinant autoantigens are produced in the baculovirus / insect cell expression system. They all have a proven track record for quality and sensitivity.
Ordering Information
12900 12901
Histidyl-tRNA Synthetase (Jo-1) 0.1 mg 1.0 mg
15600 15601
15700 15701
Threonyl-tRNA Synthetase (PL-7)
Alanyl-tRNA Synthetase (PL-12)
0.1 mg 1.0 mg
0.1 mg 1.0 mg
11100 11101
30100 30101
18400 18401
16000 16001
17000 17001
18100 18101
11000 11001
30000 30001
Glycyl-tRNA Synthetase (EJ)
Asparaginyl-tRNA Synthetase (KS)
SRP54
PM/Scl 100
PM/Scl 75
Mi-2
TIF1 gamma
MDA5
0.1 mg 1.0 mg
0.1 mg 1.0 mg
0.1 mg 1.0 mg
0.1 mg 1.0 mg
0.1 mg 1.0 mg
0.1 mg 1.0 mg
0.1 mg 1.0 mg
0.1 mg 1.0 mg
Figure: Immunodot analyses of negative (BD) and positive samples (PS1 - PS 8) for myositis. The presense of myositis autoantibodies was deter-mined by spotting decreasing amounts of selected recombinant myosi-tis antigens produced in the baculovirus / insect cell expression system. Proteins and controls (HSA, anti-IgGMA and hum IgG) were printed on nitrocellulose membrane as indicated.
References: Betteridge et al. (2011) Arthritis Research & Therapy. 13:209-215Hoshino et al. (2010) Rheumatology. 49:1726-1733
In some countries the use of certain antigens in diagnostic tests may be protected by patents. DIARECT is not responsible for the determination of these issues and suggests clarification prior to use.
HSA
anti-
IgG
MA
hum
IgG
HSA
anti-
IgG
MA
hum
IgG
Jo-1PL-7PL-12EJKSSRP54Mi-2
TIF1 gamma
MDA5PM/Scl 100PM/Scl 75
HSA
anti-
IgG
MA
hum
IgG
HSA
anti-
IgG
MA
hum
IgG
Jo-1PL-7PL-12EJKSSRP54Mi-2
TIF1 gamma
MDA5PM/Scl 100PM/Scl 75
HSA
anti-
IgG
MA
hum
IgG
HSA
anti-
IgG
MA
hum
IgG
Jo-1PL-7PL-12EJKSSRP54Mi-2
TIF1 gamma
MDA5PM/Scl 100PM/Scl 75
PS 4
PS 1 PS 2
PS 5
PS 7 PS 8
HSA
anti-
IgG
MA
hum
IgGPS 3
HSA
anti-
IgG
MA
hum
IgGPS 6
HSA
anti-
IgG
MA
hum
IgGBD
![Version 2 Please don’t nore this - Blood · Inflammatory myopathies – inclusion body myositis (IBM) (formerly Inflammatory myopathies: polymyositis [PM], dermatomyositis [DM]](https://static.fdocuments.net/doc/165x107/602246494e545541c973d779/version-2-please-donat-nore-this-blood-inflammatory-myopathies-a-inclusion.jpg)
